Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management
Authors:
- Sho ShimohamaSSSho Shimohama
- Toshiki TezukaTTToshiki Tezuka
- Keisuke TakahataKTKeisuke Takahata
- Shogyoku BunSBShogyoku Bun
- Hajime TabuchiHTHajime Tabuchi
- Morinobu SekiMSMorinobu Seki
- Yuki MomotaYMYuki Momota
- Natsumi SuzukiNSNatsumi Suzuki
- Ayaka MorimotoAMAyaka Morimoto
- Yu IwabuchiYIYu Iwabuchi
- Masahito KubotaMKMasahito Kubota
- Yasuharu YamamotoYYYasuharu Yamamoto
- 17 January 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (3) , E264-E274
Abstract
Background and Objectives: Previous studies have evaluated the diagnostic effect of amyloid positron emission tomography (PET) in selected research cohorts. However, these studies did not assess the clinical impact of the combination of amyloid and tau PETs. Our objective was to evaluate the association of the combination of two PETs with changes in diagnosis, treatment, and management in a memory clinic cohort. Methods: All participants underwent amyloid [18F]florbetaben PET and tau PET using [18F]PI-2620 or [18F]Florzolotau, which are potentially useful for the diagnosis of non-Alzheimer’s disease (AD) tauopathies. Dementia specialists determined a pre- and post-PET diagnosis that existed in both a clinical syndrome (cognitive normal [CN], mild cognitive impairment [MCI], and dementia) and suspected etiology, with a confidence level. In addition, the dementia specialists determined patient treatment in terms of ancillary investigations and management. Results: Among 126 registered participants, 84.9% completed the study procedures and were included in the analysis (CN [n=40], MCI [n=25], AD [n=20], non-AD dementia [n=22]). The etiologic diagnosis changed in 25.0% in the CN, 68.0% in the MCI, and 23.8% with dementia. Overall changes in management between pre- and post-PET occurred in 5.0% of CN, 52.0% of MCI, and 38.1% of dementia. Logistic regression analysis revealed that tau PET has stronger associations with change management than amyloid PET in all participants and dementia groups. Discussion: The combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia, and the second-generation tau-PET has a strong impact on the changes in diagnosis and management in memory clinics. Classification of evidence: This study provides Class I evidence that the combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia.Keywords
This publication has 30 references indexed in Scilit:
- Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Low amyloid‐β deposition correlates with high education in cognitively normal older adults: a pilot studyInternational Journal of Geriatric Psychiatry, 2014
- Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal ControlsNeuron, 2013
- Criteria for the diagnosis of corticobasal degenerationNeurology, 2013
- Association of Lifetime Cognitive Engagement and Low β-Amyloid DepositionArchives of Neurology, 2012
- Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementiaBrain, 2011
- Clinical amyloid imaging in Alzheimer's diseaseThe Lancet Neurology, 2011
- Classification of primary progressive aphasia and its variantsNeurology, 2011
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991